Search Results
Results for: ""
Webcast: Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results
Crinetics company management will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
READ MORE →Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports third quarter 2025 financial results and provided a business update on November 6, 2025 at 4:30PM ET.
READ MORE →NANETS 2025: Reimagining Treatment for Carcinoid Syndrome
Tom BeveridgeGlobal Product Lead, Paltusotine for Carcinoid Syndrome For individuals living with carcinoid syndrome (CS), a condition caused by neuroendocrine...
READ MORE →Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid...
READ MORE →Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an...
READ MORE →Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
SAN DIEGO – October 6, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter...
READ MORE →A New Era in Acromegaly Care: Putting Patients at the Center
Isabel KalofonosChief Commercial Officer, Crinetics Pharmaceuticals For years, people living with acromegaly have navigated a care landscape that has remained...
READ MORE →Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults
Crinetics announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with...
READ MORE →FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Crinetics will host an investor conference call on September 25, at 6:00 pm Eastern Time to discuss the FDA approval...
READ MORE →Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an...
READ MORE →Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
